Innovations, challenges and future prospects of oncoproteomics
- PMID: 19383334
- PMCID: PMC5527761
- DOI: 10.1016/j.molonc.2008.05.003
Innovations, challenges and future prospects of oncoproteomics
Abstract
Oncoproteomics is playing an increasingly important role in the diagnosis and management of cancer as well as in the development of personalized treatment of cancer. Innovative proteomic technologies relevant to cancer are described briefly, which are helping in the understanding of mechanism of drug resistance in cancer and will provide some leads to improve the management. Most important of these are nanoproteomics, i.e. application of nanobiotechnology to proteomics is playing an important role in nanooncology. Examples of some cancers will be given to point out the challenges and future prospects of oncoproteomics including those involving translation of technologies from the bench to the bedside.
Figures

Similar articles
-
Recent advances in clinical oncoproteomics.J BUON. 2007 Sep;12 Suppl 1:S31-8. J BUON. 2007. PMID: 17935275 Review.
-
Oncoproteomics: Trials and tribulations.Proteomics Clin Appl. 2016 Apr;10(4):516-31. doi: 10.1002/prca.201500081. Epub 2015 Dec 9. Proteomics Clin Appl. 2016. PMID: 26518147 Review.
-
Oncoproteomics: current trends and future perspectives.Expert Rev Proteomics. 2007 Jun;4(3):401-10. doi: 10.1586/14789450.4.3.401. Expert Rev Proteomics. 2007. PMID: 17552924 Review.
-
Mass spectrometry in diagnostic oncoproteomics.Cancer Invest. 2005;23(5):465-78. doi: 10.1081/cnv-67182. Cancer Invest. 2005. PMID: 16193645 Review.
-
Role of oncoproteomics in the personalized management of cancer.Expert Rev Proteomics. 2004 Jun;1(1):49-55. doi: 10.1586/14789450.1.1.49. Expert Rev Proteomics. 2004. PMID: 15966798 Review.
Cited by
-
Immunoexpression analysis and prognostic value of BLCAP in breast cancer.PLoS One. 2012;7(9):e45967. doi: 10.1371/journal.pone.0045967. Epub 2012 Sep 25. PLoS One. 2012. PMID: 23049907 Free PMC article.
-
Cancer secretomics reveal pathophysiological pathways in cancer molecular oncology.Mol Oncol. 2010 Dec;4(6):496-510. doi: 10.1016/j.molonc.2010.09.001. Epub 2010 Sep 16. Mol Oncol. 2010. PMID: 20934395 Free PMC article. Review.
-
Tissue proteomics of the human mammary gland: towards an abridged definition of the molecular phenotypes underlying epithelial normalcy.Mol Oncol. 2010 Dec;4(6):539-61. doi: 10.1016/j.molonc.2010.09.005. Epub 2010 Oct 8. Mol Oncol. 2010. PMID: 21036680 Free PMC article.
-
Review on early technology assessments of nanotechnologies in oncology.Mol Oncol. 2009 Dec;3(5-6):394-401. doi: 10.1016/j.molonc.2009.05.001. Epub 2009 May 20. Mol Oncol. 2009. PMID: 19540817 Free PMC article. Review.
-
A single lysis solution for the analysis of tissue samples by different proteomic technologies.Mol Oncol. 2008 Dec;2(4):368-79. doi: 10.1016/j.molonc.2008.09.003. Epub 2008 Oct 2. Mol Oncol. 2008. PMID: 19383358 Free PMC article.
References
-
- Cho, W.C. , Cheng, C.H. , 2007. Oncoproteomics: current trends and future perspectives. Expert Rev. Proteomics 4, 401–410. - PubMed
-
- D'Amico, T.A. , 2008. Molecular biologic staging of lung cancer. Ann. Thorac. Surg. 85, S737–S742. - PubMed
-
- Drev, P. , Grazio, S.F. , Bracko, M. , 2008. Tissue microarrays for routine diagnostic assessment of HER2 status in breast carcinoma. Appl. Immunohistochem. Mol. Morphol. 16, 179–184. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources